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More than 150 years ago, German pathologistRudolf Ludwig Karl Virchow (1821-1901) de-scribed the finding of the involvement of the left
supraclavicular node in gastric cancer.1 It is now known
that a number of abdominal and thoracic malignancies have
a propensity to metastasize to this anatomic site, which is
commonly referred to as Virchow node. Cancers known
to spread to Virchow node include malignancies of the lung,
pancreas, and esophagus, and adenocarcinoma of the gastric
corpus, kidney, ovary, testicle, stomach, corpus uteri, cervix
uteri, colon, and rectum.2 Metastasis to Virchow node has
also been reported in men with prostate cancer; however,
this has generally been observed at a low frequency of only
0.5%.3
In recent years, positron emission tomography (PET) ra-
diotracers targeting prostate-specific membrane antigen
(PSMA), including 68Ga-PSMA-11 and 18F-DCFPyL, have
been increasingly used to image men with prostate cancer.4,5
PET imaging with these agents offers greatly improved sen-
sitivity over conventional imaging modalities for detect-
ing low volume sites of tumor burden.6,7 Because of the
outstanding sensitivity afforded by PSMA-targeted PET, it
can be directly visualized that many patients with ad-
vanced prostate cancer can harbor disease within Virchow
node (Fig. 1).3,7-10 This observation has served as an op-
portunity to re-explore the exemplary life and career of
Rudolf Ludwig Karl Virchow.
RUDOLF LUDWIG KARL VIRCHOW—“POPE
OF MEDICINE” IN THE 19TH CENTURY
AND SOCIAL REFORMER
Remembered as the most influential pathologist in the 19th
century, Virchow was also famous as a liberal politician and
as one of the leaders of the “Deutsche Fortschrittspartei”
(German Progressive Party), the liberal political move-
ment in Germany. In a time of competing political ide-
ologies including nationalism, socialism and conservatism,
the “Progressive Party” led the opposition to the consti-
tutional forces of the Prime Minister of Prussia, Otto von
Bismarck. However, because of his role in the 1848
“Märzrevolution” (March Revolution), Virchow was finally
forced to leave Berlin and was subsequently appointed as
the first Chair of Pathological Anatomy at the Univer-
sity of Würzburg in 1849.11,12 Five years later, the Charité
Berlin reassigned him as the first Chair of Pathological
Anatomy and Physiology due to his increasing interna-
tional popularity and reputation.11,13,14 Known as the
father of cellular pathology, Virchow established the journal
“Archiv für pathologische Anatomie und Physiologie und für
klinische Medizin” in a close collaboration with his friend
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Benno Reinhardt (1819-1852). Pursuing the goal of trans-
forming the esoteric medicine in Germany to a scientific
discipline, this journal is still with us today and is now
known as “Virchows Archiv”, the official journal of the Eu-
ropean Society of Pathology.15
As a broadly influential thinker of his day, Virchow’s
career in social science remains equally as remarkable as
his work in medicine. More specifically, he is credited with
founding the newspaper “Die medicinische Reform” (Medical
Reform), popularizing the term “social medicine,” and pro-
moting the concept of physicians serving as “attorney(s)
of the poor.” One of his most famous contributions in
medical literature is the “Report on Typhus Epidemic in Upper
Silesia.” Asked by the Education Minister of Prussia, Virchow
investigated the 1848 typhus epidemic in Upper Silesia (now
within the borders of Poland) and stated that Prussian au-
thorities had failed in preventing the outbreak of this dev-
astating disease. Outlining a revolutionary program, Virchow
emphasized the urgent need for improvement of social con-
ditions in this area, which are democratic self-government,
disestablishment of the Catholic Church, and agricul-
tural cooperatives.16-18 Another example of his contribu-
tion to social medicine is his report “Reinigung und
Entwässerung Berlins” in which, through a combination of
political power and scientific knowledge, he pushed the con-
struction of the first sewer system of Berlin.19
VIRCHOW AND HIS AFTERMATH
With close to 2000 publications, Virchow has made major
contributions to the field of cellular pathology and should
be remembered for the introduction of certain medical terms
that are still used today; Virchow defined the term “embolus”
along with its thrombosis mechanism, the word “amyloid”
and its reaction with iodine and sulphuric acid in the brain,
and the term “granuloma.”11,20,21
THE VIRCHOW NODE
Indisputably, the first description of an enlarged supracla-
vicular lymph node involved in metastatic malignancies
dates back to Virchow. In 1848, he outlined in his article
“Zur Diagnose der Krebse im Unterleibe“ (Fig. 2):
…namentlich bei Krebsen des Magens, des Pankreas, der
Eierstöcke, etc., wie sich der Prozess allmählich von den
Lymphdrüsen des Unterleibs auf die im hinteren Mediastinum
neben dem Ductus thoracicus gelegenen Drüsen fortsetzt und
Figure 1. Images from a 18F-DCFPyL PET-CT scan in a 57-year-old man with untreated, biopsy-proven Gleason 5 + 4 = 9
prostate cancer with serum prostate specific antigen level of 109.2 ng/mL. (A) Whole-body maximum intensity projection
image demonstrates extensive adenopathy including a left supraclavicular Virchow node (red arrow) as well as radiotracer-
avid lymph nodes in left cervical levels IV and V, the mediastinum (red arrowhead), the retrocrural space (thin red arrow),
the retroperitoneum (double thin red arrow), and the pelvis. The (B) CT, (C) PET, and (D) PET-CT axial images at the level
of the Virchow node show that its small size (5-mm short axis, red arrows) would make it occult on conventional anatomic
imaging and indicate the importance of molecular imaging with a PSMA-targeted agent to uncover this site of disease.
Additional axial PET-CT images through (E) the mediastinum, (F) the retrocrural space, and (G) the retroperitoneum dem-
onstrate additional involved lymph nodes (red arrowhead in [E], thin red arrow in [F], and double thin red arrow in [G])
and suggest a pathway for involvement of the Virchow node, that is, the cancer likely spread up to the cisterna chyli in the
proximity of the retrocrural node, then through the thoracic duct where it was able to establish sites of metastasis in both
the mediastinum and left supraclavicular fossa. CT, computed tomography; PET, positron emission tomography; PET-CT,
positron emission tomography-computed tomography; PSMA, prostate-specific membrane antigen. (Color version available
online.)
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endlich bis auf die Jugulardrüsen fortkriecht, welche rings um
die Einmündungsstelle des Ductus thoracicus (in der linken
Supraclavicular-Grube…1
This part has been translated by Morgenstern in 1979:
…Thus, particularly in cancer of the stomach, the pancreas,
the ovaries, etc. the process gradually spreads from the glands
of the lower abdomen to the glands in the posterior mediasti-
num along the ductus thoracicus and finally involves the jugular
glands around the junction of the ductus thoracicus (in the left
supraclavicular fossa)….22
In 1889, Charles-Emile Troisier (1844-1919) also re-
ported on the findings in 27 cases of gastric carcinoma and
noted a palpable, hard, left supraclavicular node being
present.23 It has been thought that the cancerous enlarge-
ment of the left supraclavicular node at the junction of the
thoracic duct and the left subclavian vein, and the ten-
dency of gastric carcinoma to metastasize toward this region
are related to tumor emboli migration through the tho-
racic duct. The thoracic duct is a continuation of the cis-
terna chyli at the L1 level, which then enters the thoracic
cavity through the aortic hiatus and continues in the pos-
terior mediastinum between the aorta and azygos vein.24
The duct drains lymphatic fluid into the angle of the left
subclavian and internal jugular veins. The end node of the
thoracic duct is the so-called Virchow node and is located
near or at this jugulo-subclavian venous junction.25 The
involvement of the Virchow node by metastasis can be seen
in several types of cancer. Viacava and Pack investigated
4365 patients suffering from abdominal and thoracic tumors
and found an enlarged Virchow node in 2.8% of the
patients.2 The highest frequency was observed in patients
suffering from cancers of the lung, pancreas, esophagus,
kidney, ovary, testicle, stomach, prostate, corpus uteri, cervix
uteri, and rectum.2 Despite its first description more than
150 years ago, the underlying anatomy of the thoracic duct
end node has just been investigated more recently. More
specifically, in 2005, Mizutani et al found that the tho-
racic duct is divided into 3-10 several collateral ducts and
these ducts surround the Virchow node.25
CONCLUSION
The first description of the pathologic enlargement of the
left supraclavicular node in gastric cancer was provided by
Virchow in 1848. A number of other malignancies are now
known to spread to this anatomic site. Whereas prostate
cancer has not classically been thought to have a propen-
sity for metastasizing to the Virchow node, advances in mo-
lecular imaging have revealed the contrary. The prevalent
involvement of the Virchow node in prostate cancer has
likely been underestimated in the past due to our inabil-
ity to effectively characterize non–pathologically en-
larged lymph nodes in this patient population. More than
one and a half centuries after its first description, this in
vivo detection of supraclavicular lymphadenopathy using
prostate molecular imaging emphasizes the importance of
the insightful and visionary work of Dr. Virchow. Further
studies on the nature of the prostate cancer cells that are
disseminated to the Virchow node may shed light on the
Figure 2. (A) Original German article, “Zur Diagnose der Krebse im Unterleibe” by Rudolf Karl Ludwig Virchow, published in
the Medicinische Reform (45:248) in 1848. The article is within the section titled “Kleinere Mittheilungen” (Brief Commu-
nication). Description of the Virchow node and the name of the author (Virchow) were both highlighted in a red frame. (B)
Excerpt of “Zur Diagnose der Krebse im Unterleibe” showing the magnified paragraph of the Virchow node description (upper
red frame). The lower red frame highlights the name “Dr. Rud. Virchow”, who is the author of the article and the editor-in-
chief of the journal “Medicinische Reform”. (Universitätsbibliothek Heidelberg/Zur Diagnose der Krebse im Unterleibe/Die
Medicinische Reform + Extrabl. [Signatur: Friedreich 297: 1-52.1848-49]; Seite 248). (Color version available online.)
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mechanism of prostate cancer metastases, the transition from
the oligometastatic to the polymetastatic state, and the
tumor microenvironment needed to maintain prostate
cancer cells within this unique lymph node. However, if
one might consider a molecular imaging approach to obtain
specimen from the Virchow node (eg, by performing PET-
guided biopsies), the costs for those types of studies have
to be taken into account and the risk should be balanced
against the clinical need.
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